By Chad Terhune and Dan Levine (Reuters) -One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy ...

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

The stock's fall snapped a three-day winning streak.

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...